Alnylam reports up to 83% huntingtin reduction
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported initial Phase 1b results showing that brezosiran reduced cerebrospinal fluid mutant huntingtin protein by an average of 60%–64% after three months in the highest dose group evaluated.























